08-03-2005, 06:44 PM
Serious, possibly fatal, adverse effects of a new drug may first appear only after the drug is approved for marketing by the Food and Drug Administration The failure to detect these effects is best explained by the use of which of the following in the premarketing clinical trials?
A) Healthy ratherthan ill subjects
B) Lower doses of the drug than are approved for marketing
C) Patients with positive outcomes only
D) Placebos
E) Too few subjects to detect rare events
Answer: E
A) Healthy ratherthan ill subjects
B) Lower doses of the drug than are approved for marketing
C) Patients with positive outcomes only
D) Placebos
E) Too few subjects to detect rare events
Answer: E